Landos Biopharma, Inc. (NASDAQ:LABP) Sees Large Decrease in Short Interest

Landos Biopharma, Inc. (NASDAQ:LABP) was the recipient of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 14,700 shares, a decline of 10.9% from the October 15th total of 16,500 shares. Approximately 0.5% of the shares of the company are sold short. Based on an average daily volume of 5,800 shares, the short-interest ratio is presently 2.5 days.

Institutional Trading of Landos Biopharma

Hedge funds have recently bought and sold shares of the company. HRT Financial LP acquired a new stake in shares of Landos Biopharma during the fourth quarter valued at approximately $26,000. Vanguard Group Inc. lifted its holdings in shares of Landos Biopharma by 30.6% in the third quarter. Vanguard Group Inc. now owns 166,608 shares of the company’s stock valued at $108,000 after purchasing an additional 39,053 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Landos Biopharma by 119.1% in the second quarter. Goldman Sachs Group Inc. now owns 42,800 shares of the company’s stock worth $31,000 after buying an additional 23,263 shares during the period. Renaissance Technologies LLC lifted its stake in Landos Biopharma by 14.2% in the 2nd quarter. Renaissance Technologies LLC now owns 388,732 shares of the company’s stock worth $283,000 after acquiring an additional 48,232 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in Landos Biopharma by 80.4% in the 1st quarter. Bank of America Corp DE now owns 56,321 shares of the company’s stock worth $83,000 after acquiring an additional 25,096 shares in the last quarter.

Landos Biopharma Price Performance

LABP stock opened at $3.99 on Thursday. The firm has a fifty day moving average price of $3.78 and a two-hundred day moving average price of $3.86. The firm has a market cap of $12.44 million, a price-to-earnings ratio of -1.06 and a beta of -0.71. Landos Biopharma has a 1-year low of $2.11 and a 1-year high of $6.20.

About Landos Biopharma

Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract.